Galantamine, one of only five drugs/combinations approved by the FDA to treat the symptoms of mild to moderate Alzheimer’s disease, has the potential for some patients to delay the need for full time nursing care or institutionalization. However, the currently available oral medications cannot be given immediately to patients at therapeutic doses sufficient for efficacy, and must slowly be titrated up over as many as 6-12 weeks before they can acclimate a patient to the drug (called the “titration stage”). It also causes many patients to experience significant side effects, including nausea, vomiting, and diarrhea. Consequentially, caregivers are challenged by patients taking this medication due to these adverse side effects.